Spots Global Cancer Trial Database for A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies
Official Title: A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies
Study ID: NCT02958397
Conditions
Interventions
Study Description
Brief Summary: The overall purpose of this study is to explore the therapeutic effect of CD33-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Myeloid Malignancies.
Detailed Description: Great progress has been made in the treatment of relapsed and refractory B cell malignancies with CD19-targeted CAR-T cells. However, for myeloid malignancies, which has higher morbidity, trials of CAR-T is few. CD33 is expressed on most myeloid leukemia cells so it is a ideal target for CAR-T. This trial is designed and conducted to test the safety and effectiveness of CD33-targeted CAR-T.
Keywords
Eligibility
Minimum Age: 14 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Southwest Hospital of Third Millitary Medical University, Chongqing, Chongqing, China
Contact Details
Name: Cheng Qian, MD, PhD
Affiliation: Biotherapy Center of Southwest Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
